Biotage Ab Stock Fundamentals
| BIOT Stock | SEK 106.90 2.30 2.20% |
Biotage AB fundamentals help investors to digest information that contributes to Biotage AB's financial success or failures. It also enables traders to predict the movement of Biotage Stock. The fundamental analysis module provides a way to measure Biotage AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotage AB stock.
Biotage |
Biotage AB Company Operating Margin Analysis
Biotage AB's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biotage AB Operating Margin | 0.22 % |
Most of Biotage AB's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotage AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Biotage AB has an Operating Margin of 0.2179%. This is 100.62% lower than that of the Life Sciences Tools & Services sector and 104.65% lower than that of the Health Care industry. The operating margin for all Sweden stocks is 103.95% lower than that of the firm.
Biotage AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotage AB's current stock value. Our valuation model uses many indicators to compare Biotage AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotage AB competition to find correlations between indicators driving Biotage AB's intrinsic value. More Info.Biotage AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.61 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biotage AB is roughly 1.64 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotage AB's earnings, one of the primary drivers of an investment's value.Biotage Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotage AB's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotage AB could also be used in its relative valuation, which is a method of valuing Biotage AB by comparing valuation metrics of similar companies.Biotage AB is currently under evaluation in operating margin category among its peers.
Biotage Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 12.84 B | |||
| Shares Outstanding | 65.98 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 64.57 % | |||
| Price To Earning | 38.27 X | |||
| Price To Book | 8.12 X | |||
| Price To Sales | 8.04 X | |||
| Revenue | 1.23 B | |||
| Gross Profit | 755 M | |||
| EBITDA | 347 M | |||
| Net Income | 269 M | |||
| Cash And Equivalents | 311 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 180 M | |||
| Debt To Equity | 26.40 % | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 24.23 X | |||
| Cash Flow From Operations | 353 M | |||
| Earnings Per Share | 3.73 X | |||
| Target Price | 229.33 | |||
| Number Of Employees | 510 | |||
| Beta | 0.81 | |||
| Market Capitalization | 10.45 B | |||
| Total Asset | 1.99 B | |||
| Retained Earnings | 541 M | |||
| Working Capital | 212 M | |||
| Current Asset | 327 M | |||
| Current Liabilities | 115 M | |||
| Z Score | 34.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.62 % | |||
| Net Asset | 1.99 B | |||
| Last Dividend Paid | 1.55 |
About Biotage AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotage AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotage AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotage AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Biotage AB , a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions and commercial, hospitalbio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. Biotage AB operates under Medical Instruments Supplies classification in Sweden and is traded on Stockholm Stock Exchange. It employs 438 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biotage Stock Analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.